{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:59:05Z","timestamp":1793804345106,"version":"4.6.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.clinthera.2021.07.015","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T01:32:48Z","timestamp":1629509568000},"page":"1558-1573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study"],"prefix":"10.1016","volume":"43","author":[{"given":"Lisa","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathyrn","family":"Jervis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ciaccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.07.015_bib0001","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0002","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0003","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The Global Epidemiology of Diabetes and Kidney Disease","volume":"25","author":"Koye","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0004","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.amjcard.2008.08.035","article-title":"Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure","volume":"103","author":"Ekundayo","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ahj.2008.02.024","article-title":"Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality","volume":"156","author":"McCullough","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0006","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.2337\/dc06-0248","article-title":"Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients","volume":"29","author":"So","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0007","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0008","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.kint.2020.06.024","article-title":"Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment","volume":"98","author":"de Boer","year":"2020","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2021.07.015_bib0009","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1016\/j.jcjd.2017.11.004","article-title":"Chronic Kidney Disease in Diabetes","volume":"42","author":"McFarlane","year":"2018","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0010","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0011","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0012","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0013","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0014","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0015","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0016","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0017","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0018","doi-asserted-by":"crossref","unstructured":"Mann JFE, Fonseca V, Mosenzon O, et\u00a0al. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation. 2018;138:2908\u20132918.","DOI":"10.1161\/CIRCULATIONAHA.118.036418"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0019","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0020","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0021","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","article-title":"Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial","volume":"141","author":"Cannon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0022","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0023","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0024","article-title":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF","author":"Jhund","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0025","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0026","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0027","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0028","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0029","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0032","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0033","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0034","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial","volume":"57","author":"V\u00e1clav\u00edk","year":"2011","journal-title":"Hypertens Dallas Tex 1979"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0035","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J Am Soc Hypertens JASH"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0036","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0037","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0038","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11892-019-1123-8","article-title":"Mineralocorticoid Antagonism and Diabetic Kidney Disease","volume":"19","author":"Lytvyn","year":"2019","journal-title":"Curr Diab Rep"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2021.07.015_bib0039","first-page":"S1","article-title":"Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada","volume":"42","year":"2018","journal-title":"Can J Diabetes"},{"issue":"1","key":"10.1016\/j.clinthera.2021.07.015_bib0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/1753-0407.12257","article-title":"Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes: Insights into the functionally refractory patient from the LMC Diabetes Registry database","volume":"8","author":"Aronson","year":"2016","journal-title":"J Diabetes"},{"issue":"7","key":"10.1016\/j.clinthera.2021.07.015_bib0041","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jcjd.2019.04.012","article-title":"Real-World Health Outcomes of Insulin Glargine 300 U\/mL vs Insulin Glargine 100 U\/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study","volume":"43","author":"Abitbol","year":"2019","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0042","doi-asserted-by":"crossref","unstructured":"Aronson R, Chu L, Joseph N, Brown R. Prevalence and Risk Evaluation of Diabetic Complications of the Foot Among Adults With Type 1 and Type 2 Diabetes in a Large Canadian Population (PEDAL Study). Can J Diabetes. 2020. Published online December 2.","DOI":"10.1016\/j.jcjd.2020.11.011"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0043","series-title":"R: A Language and Environment for Statistical Computing","year":"2020"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0044","unstructured":"Wickham H, Fran\u00e7ois R, Henry L, M\u00fcller K.Dplyr: A Grammar of Data Manipulation. https:\/\/CRAN.R-project.org\/package=dplyr"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0045","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0046","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jcjd.2020.08.001","article-title":"Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update","volume":"44","author":"Lipscombe","year":"2020","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0047","unstructured":"System USRD. 2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. https:\/\/adr.usrds.org\/ 2020"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0048","doi-asserted-by":"crossref","DOI":"10.1177\/2054358119854113","article-title":"Characteristics of Adults With Type 2 Diabetes Mellitus by Category of Chronic Kidney Disease and Presence of Cardiovascular Disease in Alberta Canada: A Cross-Sectional Study","volume":"6","author":"Tonelli","year":"2019","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcjd.2018.06.005","article-title":"The Health and Health Care of Adults With Type 1 And 2 Diabetes Across the Spectrum of Estimated Glomerular Filtration Rates","volume":"43","author":"Clemens","year":"2019","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0050","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14401","article-title":"Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: insights from the DISCOVER study","author":"Khunti","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2020.09.016","article-title":"Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016","volume":"3","author":"Zhao","year":"2021","journal-title":"Kidney Med"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0052","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jch.13563","article-title":"Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care","volume":"21","author":"Pecoits-Filho","year":"2019","journal-title":"J Clin Hypertens Greenwich Conn"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0053","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ekir.2020.11.039","article-title":"Adherence to the Kidney Disease: Improving Global Outcomes CKD Guideline in Nephrology Practice Across Countries","volume":"6","author":"Stengel","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.clinthera.2021.07.015_bib0054","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:40Z","timestamp":1758963340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821002599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0149291821002599"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.07.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}